Huanjia Zhang

Releasing Q3 results, the Seattle-based immune system biotechnologies firm set its new full-year revenue guidance to the range of $185 million to $190 million.

University of Pittsburgh researchers showed that real-time pathogen whole-genome sequencing can help curb healthcare-associated infections within a hospital.

The company realized it is costly to develop single-disease T-Detect assays and is deferring commercialization until a clear path to reimbursement is proven.

The method, called DDNS, can identify poliovirus directly without cell culture, reducing the turnaround time for outbreak detection.

The company delivered 20 percent growth in Q2 in China, despite the country's strict COVID-19 lockdown, driven by core business growth and COVID-19 testing.

The Seattle-based company recently completed a strategic reorganization around its two major business areas by cutting the workforce and appointing a new CFO.

The South San Francisco-based startup recently published two studies showing the performance of its tests for predicting preterm birth and preeclampsia.

The multi-year project led by FIND is currently evaluating three end-to-end solutions through clinical studies. 

The diagnostics subsidiary, created by Oxford Nanopore Technologies last year, plans to forge partnerships with clinical and industry partners.

The Seattle-based company recently published immune repertoire data showing the potential of T-cell receptor profiling in IBD diagnostics.